ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Late-stage clinical development expense by Quarter
Late-stage clinical development expense ($M) ($M)
Eli Lilly Late-stage clinical development expense: $2,368M in Q2 2026, up 8.6% from a year earlier. That is the highest of the 10 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Segment Reporting Note (ASC 280-10-50-25A).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Late-stage clinical development expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,368 | +8.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,244 | +28.7% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,316 | +17.1% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,216 | +27.4% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,180 | +29.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,744 | +4.4% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,979 | – | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,739 | – | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,686 | – | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,671 | – | Form 10-Q (filed 2025-05-01) ↗ |
Cite this data
StockData. (2026). Eli Lilly Late-stage clinical development expense ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rd-exp-late-stage
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.